Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in
Patients with Relapsed and Refractory Multiple Myeloma
SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.
The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.
"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."
The trial will evaluate the overall response rate (ORR) for two cycles
of carfilzomib in patients with multiple myeloma who have previously
received specific FDA-approved therapies, have relapsed after two or more
of such therapies, and are refractory to the most recently received
therapy. Secondary objectives of this study include safety and
Copyright©2007 PR Newswire.